1 / 16

ARV Drugs : Brazilian Innovation System and the Importance for BRICS Countries

ARV Drugs : Brazilian Innovation System and the Importance for BRICS Countries. José Eduardo Cassiolato Luiz Antônio Elias Graziela Ferrero Zucoloto. Main objective: to present the Brazilian Innovation System in ARV Drugs:. General characteristics: World :

ifama
Download Presentation

ARV Drugs : Brazilian Innovation System and the Importance for BRICS Countries

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. ARV Drugs:Brazilian Innovation System and the Importance for BRICS Countries José Eduardo Cassiolato Luiz Antônio Elias Graziela Ferrero Zucoloto

  2. Main objective: to present the Brazilian Innovation System in ARV Drugs:

  3. General characteristics: World: - 40 million people living with Aids - Sub-Saharan Africa: around 2/3 of total cases in the world (25,4 million); 3/4 female. Brazil: 433 thousand cases of Aids (1980-2006 / Health Ministry)

  4. Public Expenditures on the Aquisition of ARV Drugs Source: Health Ministry

  5. ARVs Producers 70,0% 59,9% 59,3% 60,0% 53,9% 56,9% 56,3% 51,0% 48,6% 52,0% 50,0% 43,4% 37,3% 40,8% 43,1% 43,1% 45,7% 47,2% 40,0% 39,5% 39,1% 38,3% 38,3% 36,4% 30,0% 20,0% 15,8% 12,3% 10,0% 4,3% 1,8% 1,9% 2,3% 0,0% 7,1% 7,7% 6,4% 0,0% 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005* Public Labs Private Domestic Labs Foreign Labs Participation of labs in the production of ARVs purchased by “National Program / Aids” (Health Ministry) units Source: Health Ministry Obs: in 2005 the aquisitions were complemented by Unicef and other institutions.

  6. Production of ARVs 90,0% 77,0% 77,7% 75,5% 81,7% 80,0% 70,0% 70,7% 57,7% 57,8% 72,8% 55,4% 60,0% 63,7% 50,0% 39,4% 40,0% 34,7% 27,3% 25,6% 30,0% 23,6% 25,1% 19,5% 16,6% 20,0% 22,0% 19,6% 11,2% 7,7% 18,9% 5,5% 10,0% 3,5% 2,0% 2,8% 0,8% 1,7% 0,3% 0,0% 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 Public Labs Private Domestic Labs Foreign Labs Participation of labs in the production of ARVs purchased by Health Ministry - Value of production Source: Health Ministry

  7. Active Pharmaceutical Ingredients Public laboratories purchases 2005 2004 2003 Total Nac. Import. Total Nac. Import. Total Nac. Import. API (US$) (%) (US$) (%) (US$) (%) Anti-retrovirais 20.306.497 8,9% 91,1% 6.508.519 24,6% 75,4% 14.979.657 27,4% 72,6% Didanosina 2.627.384 3,6% 96,4% 457.771 10,5% 89,5% 0 - - Estavudina 1.157.894 49,5% 50,5% 316.576 90,0% 10,0% 226.953 49,3% 50,7% Lamivudina 4.425.345 1,7% 98,3% 2.481.393 18,2% 81,8% 3.213.662 45,2% 54,8% Sulfato de Indinavir 2.131.448 0,0% 100,0% 0 - - 1.691.207 0,0% 100,0% Zidovudina 9.964.426 10,7% 89,3% 3.252.779 25,0% 75,0% 9.847.835 25,7% 74,3% Outros APIs 811.225 15,0% 85,0% 930.925 28,8% 71,2% 558.434 29,6% 70,4% Total 21.117.722 9,2% 90,8% 7.439.444 25,1% 74,9% 15.538.091 27,4% 72,6% . . Source: Abifina

  8. S&T Public Infrastructure: Internationally, universities and public research institutes : - are responsible for most innovations in the health sector. -- ARVs (AZT, ddI, ddC e Abacavir) were created by North American public organizations - concentrate the basic research (riskier and more expensive) - are responsible for the most innovative discoveries, while the private enterprises are proportionally more concentrated in “me-too” -> Private enterprises: their costs are not as high as they say!

  9. S&T public infrastructure: Brazil: - highly qualified research institutions in the health area: -- Fiocruz; -- 546 research groups in HIV and other STDs; - partnership between universities and private enterprises

  10. The role of the State -> Public purchases (Law 8.666): obtain the lowest price (without considering the industrial development) -> Products specifications (APIs): - legally: same technical specifications - Imports do not respect the required specifications (around 30%) - Domestic enterprises: purify these APIs -> ↑ costs not considered. -> Trend: weakness in national production -> ↓ in bargaining power of the government ->Tendency: national production not viable -> ↑ costs

  11. Possibilities: - Law of Innovation: If a competitive company realizes locally its R&D, the criterion of the lowest price is eliminated; -- An increase in the partnerships between companies, universities, and public research institutes. - Law 11.196: Public bodies can create auctions for the acquisition of products made in Brazil that involve high technology.

  12. In summary: The segment could become competitive if its relationship with the government were altered: - Alteration in the policy of public purchases; - Stimulation of industrial and technological development; - Equal laws with imported products – taxing is qualitative. WHO Goal: to attend until 2010 to the seven million individuals carrying the HIV virus - With the productive capacity of ARVs presently existing in the world, this goal will not be attained -> there exists space in the international scene for new producers.

  13. Intellectual Property - New rules have not increased the technological activities in Brazil. There exist legal resources (flexible with safeguards) permitted by TRIPS that are not being explored in Brazil: • Compulsory Licensing -> local production of drugs patented without authorization by the holder of the patent. Threat from CL: • Believable only if the country has productive capacity; • Fundamental to negotiate with the MNCs. • Chance of retaliation?

  14. Conclusions - Presently, Brazil has the capacity to produce ARVs. - There are few technical bottlenecks. - But Brazil tends to lose this capacity for the following reasons: - Public policies don’t give enough privileges for technical-industrial development - It doesn’t utilize the flexibility permitted by TRIPS.

  15. Brazil, India e South Africa Main interests in the production of ARVs: - Lowering the costs, making the treatment viable • Strengthen national industries. IBAS: - Generate new partnerships between these countries on questions related to AIDS. - Negotiation with multinational companies. South Africa: - AIDS : a grave epidemic - Strict patent legislation without this having culminated in a strengthening of national production.

  16. Brazil, India and South Africa India: - took advantage of the period of transition permitted by TRIPS. - Via reverse engineering, India developed a competitive industry of generics and API: - Currently, it possesses several prominent pharmaceutical companies. - With complete adoption of TRIPS, how will this industry continue being competitive? - Could the Indian competitiveness be a threat to the development of the Brazilian industry?

More Related